stockportfolio.pro
Gyre Therapeutics, Inc. (GYRE)
Healthcare · Biotechnology · NasdaqCM
Gyre Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.02M | $6,000 | $0 | $20.95M | $7.34M | $102.29M | $113.45M | $105.76M | $116.59M |
| Gross profit | — | — | — | — | — | — | $97.50M | $108.81M | $101.87M | $111.17M |
| Net income | $-16.95M | $-21.56M | $-30.05M | $-55.18M | $-56.24M | $-87.93M | $2.30M | $-92.93M | $12.09M | $5.03M |
| Net margin | — | -2118.0% | -500916.7% | — | -268.5% | -1198.3% | 2.3% | -81.9% | 11.4% | 4.3% |
Source: Gyre Therapeutics, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Gyre Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GYRE in your portfolio →
Gyre Therapeutics, Inc. financial history by metric
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. — frequently asked questions
What is Gyre Therapeutics, Inc.'s revenue?
Gyre Therapeutics, Inc. (GYRE) reported revenue of $116.59M for fiscal year 2025, up 10.2% from the prior year, according to its SEC filings.
Is Gyre Therapeutics, Inc. profitable?
Yes. GYRE earned net income of $5.03M in fiscal 2025, a net margin of 4.3%.
What is GYRE's P/E ratio?
Gyre Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Gyre Therapeutics, Inc. growing?
GYRE's revenue grew at roughly 41.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Gyre Therapeutics, Inc. have?
As of fiscal year 2025, GYRE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Gyre Therapeutics, Inc.'s gross margin?
GYRE's gross margin was 95.4% in fiscal 2025 — gross profit of $111.17M on revenue of $116.59M.
What is Gyre Therapeutics, Inc.'s market cap?
Gyre Therapeutics, Inc. (GYRE) has a market capitalization of about $602.55M, based on the latest data in our nightly-refreshed cache.
When does Gyre Therapeutics, Inc.'s fiscal year end?
GYRE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Gyre Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.